WallStSmart
ACHL

Achilles Therapeutics PLC ADR

NASDAQ: ACHL · HEALTHCARE · BIOTECHNOLOGY

$1.48
+0.00% today

Updated 2026-06-05

Market cap
$63.22M
P/E ratio
P/S ratio
EPS (TTM)
$-1.66
Dividend yield
52W range
$0 – $0
Volume
1.2M

Achilles Therapeutics PLC ADR (ACHL) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201820192020202120222023
Operating cash flow$-7598.00$-14.14M$-25.25M$-59.28M$-59.53M$-48.45M
Capital expenditures$258.00$942000.00$11.85M$7.63M$7.51M$1.10M
Depreciation
Stock-based comp$76.00$719000.00$2.99M$6.32M$7.02M$6.36M
Free cash flow$-7856.00$-15.08M$-37.10M$-66.92M$-67.05M$-49.55M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does ACHL generate?

ACHL produced $-49.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ACHL's balance sheet healthy?

ACHL holds $131.54M in cash and equivalents against — in long-term debt, on $142.37M of shareholder equity. That debt is best read against the cash flow the business throws off each year.